Abstract
摘要
相似文献
1
Malfeasance on an industrial scale.
Prescrire Int. 2013 Feb;22(135):32.
2
Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
Rev Law Soc Change. 2012;35(4):793-862.
3
GlaxoSmithKline is fined record $3bn in US.
BMJ. 2012 Jul 3;345:e4568. doi: 10.1136/bmj.e4568.
4
Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
Food Drug Law J. 2007;62(3):559-72.
5
Management of serious adverse drug reactions: proposals from a victims' organisation.
Prescrire Int. 2012 Sep;21(130):220-3.
6
Targeting drug companies' bottom line.
Prescrire Int. 2011 Jan;20(112):25.
7
Bitter pills for drug companies.
BMJ. 2010 Sep 17;341:c5095. doi: 10.1136/bmj.c5095.
8
Off-label marketing and the First Amendment.
N Engl J Med. 2013 Jan 10;368(2):103-5. doi: 10.1056/NEJMp1214926. Epub 2012 Dec 12.
9
Company pays over $81m for allegedly promoting topiramate for unapproved uses.
BMJ. 2010 May 27;340:c2848. doi: 10.1136/bmj.c2848.
10
Criminalizing knowledge: the perverse implications of the intended use regulations of off-label promotion prosecutions.
Food Drug Law J. 2009;64(3):441-58.
Zotero 插件